Iran Daru (XTEH:IRDR1) Debt-to-Revenue : 0.00 (As of . 20)

View and export this data going back to 1990. Start your Free Trial

What is Iran Daru Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Iran Daru's Short-Term Debt & Capital Lease Obligation for the quarter that ended in . 20 was IRR0.00 Mil. Iran Daru's Long-Term Debt & Capital Lease Obligation for the quarter that ended in . 20 was IRR0.00 Mil. Iran Daru's annualized Revenue for the quarter that ended in . 20 was IRR0.00 Mil.

Iran Daru Debt-to-Revenue Historical Data

The historical data trend for Iran Daru's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Iran Daru Debt-to-Revenue Chart

Iran Daru Annual Data

Trend

Debt-to-Revenue

Iran Daru Semi-Annual Data

Debt-to-Revenue

Competitive Comparison of Iran Daru's Debt-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Iran Daru's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Iran Daru's Debt-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Iran Daru's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Iran Daru's Debt-to-Revenue falls into.

Iran Daru Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Iran Daru's Debt-to-Revenue for the fiscal year that ended in . 20 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(	+	)	/	N/A
	=	N/A

Iran Daru's annualized Debt-to-Revenue for the quarter that ended in . 20 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(	+	)	/	0
	=	N/A

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is one times the quarterly (. 20) Revenue data.

Iran Daru Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Iran Daru's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Iran Daru (XTEH:IRDR1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Iran Daru (XTEH:IRDR1) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

Ayatollah Saeedi Highway, End Of Kermani Street, Moallem Boulevard, Tehran, IRN, 1371658111

Website

https://www.irandaru.com

Iran Daru is a pharmaceutical company based in Iran. It manufactures and sells pharmaceutical products for antibiotics, cardiovascular agents, and local anesthetic agents. The company manufactures products in three main dosage form categories namely solid, semi-solid, and liquid including tablets, capsules, pellets, sachets, gels, creams, ointments (sterile and non-sterile), spray solutions, and syrups. Products offered by Iran Daru include Diclofenac Potassium, Biotin 5 mg, Tetracycline, Folic acid, Meloxicam, Acetaminophen and Caffeine, and Levocetirizine dihydrochloride, among others. It also exports its products to other countries.

Iran Daru (XTEH:IRDR1) Headlines

No Headlines